Pfag, a multivalent peptide vaccine against malaria
Active Grant Awarded Last action
- Award ID
- R41AI195230
- Recipient
-
L2 Diagnostics LLC UEI GKA7VH5LFR25
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,954
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 60% complete
- Place of performance
- New Haven, CT 06511, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pfag is our novel malaria vaccine, composed of short synthetic peptides representing specific immunogenic epitopes of the plasmodium falciparum circumsporozoite (CSP) and anopheles gambiae trio (AG trio) proteins. Our prototype PF AG has yielded outstanding early results, including immunogenicity to target antigens and to achieve sterile immunity in an outbred heterogenous CD-1 mouse model. This phase I feasibility sttr project aims to (I) optimize the prototype pfag vaccine construct and (II) conduct efficacy testing to confirm the optimal construct design. Our long-term goal is to develop a novel peptide-based vaccine that can be used alone as a multivalent CSP/agtrio vaccine or CO-administered with existing pre-erythrocytic vaccines such as RTS, S and R21 for a more robust immunological initial or boost response. Our target customers include global health and government organizations calling on developing new tools to eradicate malaria. A peptide-based vaccine's safety, production, and cost profile are favorable for addressing the real-world challenges of deploying a vaccine in malaria-endemic, resource-poor countries, where the current malaria eradication approach is limited by efficacy, cost, and logistics issues.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $300,000 | |
| Original award | $299,954 |
Quick answers
Who received award R41AI195230?
R41AI195230 was awarded to L2 Diagnostics LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 15, 2025.
How much is award R41AI195230 worth?
$599,954 has been obligated on R41AI195230.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award